Menin-MLL inhibitors as a new therapeutic target for middle ear cholesteatoma.

ABSTRACT: Middle ear cholesteatoma (cholesteatoma), also known as a cholesteatomatous chronic otitis media, is concerning because it expands into the middle ear with bone destruction and causes irreversible hearing loss. Surgical resection is currently the only curative treatment, but the high recurrence rate remains a major problem, necessitating the development of novel therapies. In our previous study, we demonstrated that histone modifications are involved in the pathogenesis of cholesteatoma and that keratinocyte growth factor (KGF)-induced murine cholesteatoma is suppressed by administration of MI-503, a menin-MLL inhibitor. This study was designed to assess the therapeutic potential of menin-MLL inhibitors for the non-surgical management of cholesteatoma and to elucidate their mechanism of ac

SUBMITTER: Yamamoto-Fukuda T 

PROVIDER: S-EPMC12835526 | biostudies-literature | 2026 Jan

REPOSITORIES: biostudies-literature